The launch of Eli Lilly’s weight-loss drug Mounjaro in India has sparked a wave of interest, with some doctors reportedly receiving hundreds of patient enquiries, according to a Reuters report. The drug, priced significantly lower than in the US, is now available locally as a once-weekly injection and has become a sought-after option among patients previously reliant on overseas suppliers or the black market.

Why is Mounjaro attracting attention?
The report says that India's growing obesity crisis makes it a key market, expected to become the second-largest by 2050. Mounjaro, with its competitive pricing — starting at Rs 3,500 for a 2.5 mg dose — has undercut black market rates by more than half. A typical patient may spend around $200 per month on a 5 mg weekly dose in India. In contrast, the US price is over $1,000 a month without insurance.

How are patients and doctors responding?
Doctors and clinics surveyed by Reuters have seen a sharp spike in queries. Some patients, like one in Delhi-based Elevate Now, reportedly called over 200 times in a week. Hospitals such as Manipal in Bengaluru noted over a 20% rise in consultations. Doctors warn patients to seek proper medical advice before starting treatment.

What does this mean for rivals?
The report adds that Novo Nordisk is reconsidering its India launch plans for Wegovy, as Lilly enjoys a first-mover advantage. Meanwhile, Indian generic firms are eyeing the market, projected to hit $175 billion globally by 2035.